The study completed enrolment in 2018 and is ongoing, patients receive HER-Vaxx every three months to maintain high levels of cancer-targeting antibodies.
A phase II study was initiated in March 2019 dosing patients at the highest phase Ib dose.
The presentation given at the ASCO annual meeting in Chicago showed that by day 182 of the trial, patients dosed with the highest dose of HER-Vaxx tumours had either shrunk further or stabilised.
In one patient, their tumour has shrunk more than 70% since joining the trial.
We've just released news on our positive new 6-month data: our HER-Vaxx-chemo combination shrinks or stabilises tumour growth | Read the ASX announcement here >https://t.co/pZ5q439xSQ #MedTech #Pharma #ASCO19 (ASX: IMU) pic.twitter.com/o2lDThBVZY— Imugene | Cancer Immunotherapies (@TeamImugene) June 3, 2019
All patients on the highest dose have received their day-266 does and these results will be presented in Barcelona on 3-6 July 2019.
Imugene’s managing director and CEO Leslie Chong said: “There is continued interest in the positive data from our phase Ib trial which supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”
Last month, Imugene appointed Dr Jens Eckstein as a non-executive director to its board.
Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.
He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.
Strong pipeline of cancer vaccines in development
The company has a strong pipeline of cancer vaccines in development.